During the last session, Spyre Therapeutics Inc (NASDAQ:SYRE)’s traded shares were 0.42 million, with the beta value of the company hitting 2.98. At the end of the trading day, the stock’s price was $22.92, reflecting an intraday gain of 1.06% or $0.24. The 52-week high for the SYRE share is $47.97, that puts it down -109.29 from that peak though still a striking 12.43% gain since the share price plummeted to a 52-week low of $20.07. The company’s market capitalization is $1.35B, and the average intraday trading volume over the past 10 days was 0.6 million shares, and the average trade volume was 608.16K shares over the past three months.
Spyre Therapeutics Inc (SYRE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.27. SYRE has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.97.
Spyre Therapeutics Inc (NASDAQ:SYRE) trade information
Spyre Therapeutics Inc (SYRE) registered a 1.06% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.06% in intraday trading to $22.92, hitting a weekly high. The stock’s 5-day price performance is 1.19%, and it has moved by 5.82% in 30 days. Based on these gigs, the overall price performance for the year is 2.03%. The short interest in Spyre Therapeutics Inc (NASDAQ:SYRE) is 10.24 million shares and it means that shorts have 17.29 day(s) to cover.
The consensus price target of analysts on Wall Street is $50, which implies an increase of 54.16% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $40 and $71 respectively. As a result, SYRE is trading at a discount of -209.77% off the target high and -74.52% off the low.
Spyre Therapeutics Inc (SYRE) estimates and forecasts
In the rating firms’ projections, revenue will increase 162.10% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.33M as predicted by 9 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 4M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 23.71%. While earnings are projected to return 91.31% in 2025, the next five years will return 56.12% per annum.
SYRE Dividends
Spyre Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 4.02 million shares, is of FAIRMOUNT FUNDS MANAGEMENT LLC’s that is approximately 8.8668% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $94.47 million.
Also, the Mutual Funds coming in first place with the largest holdings of Spyre Therapeutics Inc (SYRE) shares are Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.47 shares. This amounts to just over 2.86 percent of the company’s overall shares, with a $33.72 million market value. The same data shows that the other fund manager holds slightly less at 1.37, or about 2.66% of the stock, which is worth about $31.37 million.
